Abstract
Summary
Researchers looked at data from the largest and longest-running database of children with growth disorders who were treated with daily injections of a brand of growth
Researchers showed that daily growth
○ Increased the children’s heights, measured after 1 year of treatment. This was seen for all of the growth disorders studied.
○ Increased growth in children of different ages, with higher growth seen in children who had begun treatment before they started puberty.
○ Allowed short children to reach an adult height within the normal range. This was true even for children who did not begin treatment until early adolescence.
○ Was safe. Only a very small percentage (3%) of children had any side effects related to growth
When children reach the end of puberty, their growth plates close and they are unable to grow any taller. Once this happens, growth
The results of this study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence and not on the results of a single study.
Keywords
Footnotes
Acknowledgements
The authors thank Professor Kerstin Albertsson-Wikland, who was one of the authors of the original publication and contributed to the development of this plain language summary. Had Professor Kerstin Albertsson-Wikland been alive at the time of submission, she would have met the remaining requirements of authorship and would have been included in the author byline for this summary. Writing support for this summary was provided by Chu Kong Liew, PhD, CMPP, at Envision Pharma Group, and was funded by Pfizer. All authors of the original publication (except for Professor Kerstin Albertsson-Wikland) were involved in preparing this summary and approved the content in the final version. Pfizer would like to thank all of the people who took part in this study.